Table 2.
Baseline signs, symptoms, and comorbidities for patients at the Modena centre only
|
Tocilizumab plus standard care group (n=132) |
Standard care group (n=222) | p value | All patients (n=354) | |||
|---|---|---|---|---|---|---|
| Subcutaneous (n=84) | Intravenous (n=48) | |||||
| Age (years) | 67 (56–73) | 61 (52–74) | 67 (55–78) | 0·34 | 66 (55–76) | |
| Sex | .. | .. | .. | 1·0 | .. | |
| Female | 26 (31%) | 15 (31%) | 68 (31%) | .. | 109 (31%) | |
| Male | 58 (69%) | 33 (69%) | 154 (69%) | .. | 245 (69%) | |
| Any comorbidity | 39 (46%) | 24 (50%) | 36 (16%) | <0·001 | 99 (28%) | |
| Comorbidities | ||||||
| Diabetes | 11 (13%) | 6 (13%) | 7 (3%) | 0·0008 | 24 (7%) | |
| Hypertension | 37 (44%) | 22 (46%) | 30 (14%) | <0·0001 | 89 (25%) | |
| Cardiovascular disease | 9 (11%) | 6 (13%) | 12 (5%) | 0·12 | 27 (8%) | |
| Chronic renal insufficiency | 2 (2%) | 5 (10%) | 7 (3%) | 0·045 | 14 (4%) | |
| Cancer | 2 (2%) | 0 | 8 (4%) | 0·38 | 10 (3%) | |
| Disease duration | ||||||
| Days from symptoms onset to hospitalisation | 8 (6–11) | 5 (3–9) | 5 (2–9) | 0·0016 | 7 (3–10) | |
| Days from hospitalisation to intubation | 3 (0–5) | 2 (1–4) | 2 (0–3) | 0·49 | 2 (0–4) | |
| Sign and symptoms | ||||||
| Fever (°C) | 37 (36–38) | 37 (36–38) | 37 (36–37) | 0·54 | 37 (36–37) | |
| Cough | 42 (50%) | 20 (42%) | 55 (25%) | <0·0001 | 117 (33%) | |
| Myalgia | 5 (6%) | 5 (10%) | 7 (3%) | 0·088 | 17 (5%) | |
| Sputum | 5 (6%) | 0 | 4 (2%) | 0·059 | 9 (3%) | |
| Headache | 5 (6%) | 7 (15%) | 10 (5%) | 0·032 | 22 (6%) | |
| Haemoptysis | 0 | 1 (2%) | 2 (1%) | 0·45 | 3 (1%) | |
| Systolic pressure (mm Hg) | 130 (118–138) | 120 (110–135) | 124 (110–140) | 0·36 | 125 (110–138) | |
Data are median (IQR) or n (%) unless otherwise indicated. p values were calculated using the χ2 test or Kruskal-Wallis test as appropriate.